TY - JOUR AU - Mozaffarian, D. AU - Benjamin, E. J. AU - Go, A. S. AU - Arnett, D. K. AU - Blaha, M. J. AU - Cushman, M. PY - 2016 DA - 2016// TI - Heart disease and stroke statistics-2016 update: a report from the american heart association JO - Circulation VL - 133 ID - Mozaffarian2016 ER - TY - JOUR AU - Fitchett, D. H. AU - Udell, J. A. AU - Inzucchi, S. E. PY - 2017 DA - 2017// TI - Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes JO - Eur J Heart Fail VL - 19 UR - https://doi.org/10.1002/ejhf.633 DO - 10.1002/ejhf.633 ID - Fitchett2017 ER - TY - JOUR AU - Lloyd-Jones, D. M. AU - Larson, M. G. AU - Leip, E. P. AU - Beiser, A. AU - D’Agostino, R. B. AU - Kannel, W. B. PY - 2002 DA - 2002// TI - Lifetime risk for developing congestive heart failure: the Framingham Heart Study JO - Circulation VL - 106 UR - https://doi.org/10.1161/01.CIR.0000039105.49749.6F DO - 10.1161/01.CIR.0000039105.49749.6F ID - Lloyd-Jones2002 ER - TY - JOUR AU - Owan, T. E. AU - Hodge, D. O. AU - Herges, R. M. AU - Jacobsen, S. J. AU - Roger, V. L. AU - Redfield, M. M. PY - 2006 DA - 2006// TI - Trends in prevalence and outcome of heart failure with preserved ejection fraction JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa052256 DO - 10.1056/NEJMoa052256 ID - Owan2006 ER - TY - JOUR AU - Zelniker, T. A. AU - Braunwald, E. PY - 2018 DA - 2018// TI - Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review JO - J Am Coll Cardiol VL - 72 UR - https://doi.org/10.1016/j.jacc.2018.06.040 DO - 10.1016/j.jacc.2018.06.040 ID - Zelniker2018 ER - TY - JOUR AU - Jha, V. AU - Garcia-Garcia, G. AU - Iseki, K. AU - Li, Z. AU - Naicker, S. AU - Plattner, B. AU - Saran, R. AU - Wang, A. Y. AU - Yang, C. W. PY - 2013 DA - 2013// TI - Chronic kidney disease: global dimension and perspectives JO - Lancet VL - 382 UR - https://doi.org/10.1016/S0140-6736(13)60687-X DO - 10.1016/S0140-6736(13)60687-X ID - Jha2013 ER - TY - JOUR AU - Kastarinen, M. AU - Juutilainen, A. AU - Kastarinen, H. AU - Salomaa, V. AU - Karhapää, P. AU - Tuomilehto, J. PY - 2010 DA - 2010// TI - Risk factors for end-stage renal disease in a community-based population: 26-year follow-up of 25,821 men and women in eastern Finland JO - J Intern Med VL - 267 UR - https://doi.org/10.1111/j.1365-2796.2009.02197.x DO - 10.1111/j.1365-2796.2009.02197.x ID - Kastarinen2010 ER - TY - JOUR AU - Armstrong, D. G. AU - Boulton, A. J. M. AU - Bus, S. A. PY - 2017 DA - 2017// TI - Diabetic foot ulcers and their recurrence JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMra1615439 DO - 10.1056/NEJMra1615439 ID - Armstrong2017 ER - TY - JOUR AU - Gilbert, M. P. AU - Pratley, R. E. PY - 2015 DA - 2015// TI - The impact of diabetes and diabetes medications on bone health JO - Endocr Rev VL - 36 UR - https://doi.org/10.1210/er.2012-1042 DO - 10.1210/er.2012-1042 ID - Gilbert2015 ER - TY - JOUR AU - Thomas, M. C. AU - Tsalamandris, C. AU - MacIsaac, R. J. AU - Jerums, G. PY - 2006 DA - 2006// TI - The epidemiology of hemoglobin levels in patients with type 2 diabetes JO - Am J Kidney Dis VL - 48 UR - https://doi.org/10.1053/j.ajkd.2006.06.011 DO - 10.1053/j.ajkd.2006.06.011 ID - Thomas2006 ER - TY - JOUR AU - Kaul, S. AU - Bolger, A. F. AU - Herrington, D. AU - Giugliano, R. P. AU - Eckel, R. H. PY - 2010 DA - 2010// TI - Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation JO - J Am Coll Cardiol VL - 55 UR - https://doi.org/10.1016/j.jacc.2010.02.014 DO - 10.1016/j.jacc.2010.02.014 ID - Kaul2010 ER - TY - JOUR AU - Home, P. D. AU - Pocock, S. J. AU - Beck-Nielsen, H. AU - Curtis, P. S. AU - Gomis, R. AU - Hanefeld, M. AU - Jones, N. P. AU - Komajda, M. AU - McMurray, J. J. PY - 2009 DA - 2009// TI - Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial JO - Lancet VL - 373 UR - https://doi.org/10.1016/S0140-6736(09)60953-3 DO - 10.1016/S0140-6736(09)60953-3 ID - Home2009 ER - TY - JOUR AU - Lincoff, A. M. AU - Wolski, K. AU - Nicholls, S. J. AU - Nissen, S. E. PY - 2007 DA - 2007// TI - Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JO - JAMA VL - 298 UR - https://doi.org/10.1001/jama.298.10.1180 DO - 10.1001/jama.298.10.1180 ID - Lincoff2007 ER - TY - JOUR AU - Douros, A. AU - Dell’Aniello, S. AU - Yu, O. H. Y. AU - Filion, K. B. AU - Azoulay, L. AU - Suissa, S. PY - 2018 DA - 2018// TI - Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study JO - BMJ VL - 362 UR - https://doi.org/10.1136/bmj.k2693 DO - 10.1136/bmj.k2693 ID - Douros2018 ER - TY - JOUR AU - Powell, W. R. AU - Christiansen, C. L. AU - Miller, D. R. PY - 2018 DA - 2018// TI - Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments JO - Diabetes Ther. VL - 9 UR - https://doi.org/10.1007/s13300-018-0443-z DO - 10.1007/s13300-018-0443-z ID - Powell2018 ER - TY - JOUR AU - Vaccaro, O. AU - Masulli, M. AU - Nicolucci, A. AU - Bonora, E. AU - Prato, S. AU - Maggioni, A. P. PY - 2017 DA - 2017// TI - Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial JO - Lancet Diabetes Endocrinol. VL - 5 UR - https://doi.org/10.1016/s2213-8587(17)30317-0 DO - 10.1016/s2213-8587(17)30317-0 ID - Vaccaro2017 ER - TY - JOUR AU - Zannad, F. AU - Stough, W. G. AU - Lipicky, R. J. AU - Tamargo, J. AU - Bakris, G. L. AU - Borer, J. S. PY - 2016 DA - 2016// TI - Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion JO - Eur Heart J Cardiovasc Pharmacother. VL - 2 UR - https://doi.org/10.1093/ehjcvp/pvw007 DO - 10.1093/ehjcvp/pvw007 ID - Zannad2016 ER - TY - JOUR AU - Das, S. R. AU - Everett, B. M. AU - Birtcher, K. K. AU - Brown, J. M. AU - Cefalu, W. T. AU - Januzzi, J. L. AU - Kalyani, R. R. AU - Kosiborod, M. AU - Magwire, M. L. AU - Morris, P. B. AU - Sperling, L. S. PY - 2018 DA - 2018// TI - 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American college of cardiology task force on expert consensus decision pathways JO - J Am Coll Cardiol VL - 72 UR - https://doi.org/10.1016/j.jacc.2018.09.020 DO - 10.1016/j.jacc.2018.09.020 ID - Das2018 ER - TY - JOUR AU - Scheen, A. J. AU - Paquot, N. PY - 2018 DA - 2018// TI - Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018 JO - Rev Med Liege VL - 73 ID - Scheen2018 ER - TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Mattheus, M. AU - Devins, T. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. AU - Inzucchi, S. E. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/nejmoa1504720 DO - 10.1056/nejmoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Neal, B. AU - Perkovic, V. AU - Mahaffey, K. W. AU - Zeeuw, D. AU - Fulcher, G. AU - Erondu, N. AU - Shaw, W. AU - Law, G. AU - Desai, M. AU - Matthews, D. R. PY - 2017 DA - 2017// TI - Canagliflozin and cardiovascular and renal events in type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/nejmoa1611925 DO - 10.1056/nejmoa1611925 ID - Neal2017 ER - TY - JOUR AU - Wiviott, S. D. AU - Raz, I. AU - Bonaca, M. P. AU - Mosenzon, O. AU - Kato, E. T. AU - Cahn, A. AU - Silverman, M. G. AU - Zelniker, T. A. AU - Kuder, J. F. AU - Murphy, S. A. AU - Bhatt, D. L. AU - Leiter, L. A. AU - McGuire, D. K. AU - Wilding, J. P. H. AU - Ruff, C. T. AU - Gause-Nilsson, I. A. M. AU - Fredriksson, M. AU - Johansson, P. A. AU - Langkilde, A. M. AU - Sabatine, M. S. PY - 2019 DA - 2019// TI - Dapagliflozin and cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/nejmoa1812389 DO - 10.1056/nejmoa1812389 ID - Wiviott2019 ER - TY - JOUR AU - Perkovic, V. AU - Jardine, M. J. AU - Neal, B. AU - Bompoint, S. AU - Heerspink, H. J. L. AU - Charytan, D. M. AU - Edwards, R. AU - Agarwal, R. AU - Bakris, G. AU - Bull, S. AU - Cannon, C. P. AU - Capuano, G. AU - Chu, P. L. AU - Zeeuw, D. AU - Greene, T. AU - Levin, A. AU - Pollock, C. AU - Wheeler, D. C. AU - Yavin, Y. AU - Zhang, H. AU - Zinman, B. AU - Meininger, G. AU - Brenner, B. M. AU - Mahaffey, K. W. PY - 2019 DA - 2019// TI - Canagliflozin and renal outcomes in type 2 diabetes and nephropathy JO - N Engl J Med VL - 1 UR - https://doi.org/10.1056/nejmoa1811744 DO - 10.1056/nejmoa1811744 ID - Perkovic2019 ER - TY - JOUR AU - Altman, D. G. AU - Bland, J. M. PY - 2011 DA - 2011// TI - How to obtain the P value from a confidence interval JO - BMJ VL - 343 UR - https://doi.org/10.1136/bmj.d2304 DO - 10.1136/bmj.d2304 ID - Altman2011 ER - TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Mattheus, M. AU - Devins, T. AU - Johansen, O. E. AU - Woerle, H. J. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - STD TI - Jardiance. Drugs website. 2019. https://www.drugs.com/pro/jardiance.html. Accessed 22 Apr 2019. UR - https://www.drugs.com/pro/jardiance.html ID - ref26 ER - TY - JOUR AU - Zinman, B. AU - Inzucchi, S. E. AU - Lachin, J. M. AU - Wanner, C. AU - Ferrari, R. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Kempthorne-Rawson, J. AU - Newman, J. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2014 DA - 2014// TI - Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA–REG OUTCOME™) JO - Cardiovasc Diabetol. VL - 19 UR - https://doi.org/10.1186/1475-2840-13-102 DO - 10.1186/1475-2840-13-102 ID - Zinman2014 ER - TY - JOUR AU - Wanner, C. AU - Inzucchi, S. E. AU - Lachin, J. M. AU - Fitchett, D. AU - Eynatten, M. AU - Mattheus, M. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. AU - Zinman, B. PY - 2016 DA - 2016// TI - Empagliflozin and progression of kidney disease in type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/nejmoa1515920 DO - 10.1056/nejmoa1515920 ID - Wanner2016 ER - TY - JOUR AU - Neal, B. AU - Perkovic, V. AU - Zeeuw, D. AU - Mahaffey, K. W. AU - Fulcher, G. AU - Stein, P. AU - Desai, M. AU - Shaw, W. AU - Jiang, J. AU - Vercruysse, F. PY - 2013 DA - 2013// TI - Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial JO - Am Heart J VL - 166 UR - https://doi.org/10.1016/j.ahj.2013.05.007 DO - 10.1016/j.ahj.2013.05.007 ID - Neal2013 ER - TY - STD TI - Invokana. Drugs website. 2018. https://www.drugs.com/pro/invokana.html. Accessed 22 Apr 2019. UR - https://www.drugs.com/pro/invokana.html ID - ref30 ER - TY - JOUR AU - Neuen, B. L. AU - Ohkuma, T. AU - Neal, B. AU - Matthews, D. R. AU - Zeeuw, D. AU - Mahaffey, K. W. AU - Fulcher, G. AU - Desai, M. AU - Li, Q. AU - Deng, H. AU - Rosenthal, N. AU - Jardine, M. J. AU - Bakris, G. AU - Perkovic, V. PY - 2018 DA - 2018// TI - Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function JO - Circulation VL - 138 UR - https://doi.org/10.1161/CIRCULATIONAHA.118.035901 DO - 10.1161/CIRCULATIONAHA.118.035901 ID - Neuen2018 ER - TY - JOUR AU - Wiviott, S. D. AU - Raz, I. AU - Bonaca, M. P. AU - Mosenzon, O. AU - Kato, E. T. AU - Cahn, A. AU - Silverman, M. G. AU - Bansilal, S. AU - Bhatt, D. L. AU - Leiter, L. A. AU - McGuire, D. K. AU - Wilding, J. P. AU - Gause-Nilsson, I. A. AU - Langkilde, A. M. AU - Johansson, P. A. AU - Sabatine, M. S. PY - 2018 DA - 2018// TI - The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial JO - Am Heart J VL - 200 UR - https://doi.org/10.1016/j.ahj.2018.01.012 DO - 10.1016/j.ahj.2018.01.012 ID - Wiviott2018 ER - TY - STD TI - Farxiga. Drugs website. 2019. https://www.drugs.com/pro/farxiga.html. Accessed 22 Apr 2019. UR - https://www.drugs.com/pro/farxiga.html ID - ref33 ER - TY - STD TI - Blair G. New FDA Extension for Farxiga and Xigduo XR. Diabetes in Control website. 2019. http://www.diabetesincontrol.com/new-fda-extension-for-farxiga-and-xigduo-xr/. Accessed 10 May 2019. UR - http://www.diabetesincontrol.com/new-fda-extension-for-farxiga-and-xigduo-xr/ ID - ref34 ER - TY - JOUR AU - Kluger, A. Y. AU - Tecson, K. M. AU - Barbin, C. M. AU - Lee, A. Y. AU - Lerma, E. V. AU - Rosol, Z. P. AU - Rangaswami, J. AU - Lepor, N. E. AU - Cobble, M. E. AU - McCullough, P. A. PY - 2018 DA - 2018// TI - Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA–REG OUTCOME trials: a systematic review JO - Rev Cardiovasc Med VL - 19 UR - https://doi.org/10.31083/j.rcm.2018.02.907 DO - 10.31083/j.rcm.2018.02.907 ID - Kluger2018 ER - TY - JOUR AU - Matsushita, K. AU - Velde, M. AU - Astor, B. C. AU - Woodward, M. AU - Levey, A. S. AU - Jong, P. E. AU - Coresh, J. AU - Gansevoort, R. T. PY - 2010 DA - 2010// TI - Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis JO - Lancet VL - 375 UR - https://doi.org/10.1016/s0140-6736(10)60674-5 DO - 10.1016/s0140-6736(10)60674-5 ID - Matsushita2010 ER - TY - JOUR AU - McCullough, P. A. AU - Li, S. AU - Jurkovitz, C. T. AU - Stevens, L. A. AU - Wang, C. AU - Collins, A. J. AU - Chen, S. C. AU - Norris, K. C. AU - McFarlane, S. I. AU - Johnson, B. AU - Shlipak, M. G. AU - Obialo, C. I. AU - Brown, W. W. AU - Vassalotti, J. A. AU - Whaley-Connell, A. T. PY - 2008 DA - 2008// TI - CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004 JO - Am J Kidney Dis VL - 51 UR - https://doi.org/10.1053/j.ajkd.2007.12.017 DO - 10.1053/j.ajkd.2007.12.017 ID - McCullough2008 ER - TY - JOUR AU - Zelniker, T. A. AU - Wiviott, S. D. AU - Raz, I. AU - Im, K. AU - Goodrich, E. L. AU - Bonaca, M. P. AU - Mosenzon, O. AU - Kato, E. T. AU - Cahn, A. AU - Furtado, R. H. M. AU - Bhatt, D. L. AU - Leiter, L. A. AU - McGuire, D. K. AU - Wilding, J. P. H. AU - Sabatine, M. S. PY - 2019 DA - 2019// TI - SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials JO - Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32590-X DO - 10.1016/S0140-6736(18)32590-X ID - Zelniker2019 ER - TY - JOUR AU - Stevens, L. A. AU - Li, S. AU - Kurella Tamura, M. AU - Chen, S. C. AU - Vassalotti, J. A. AU - Norris, K. C. AU - Whaley-Connell, A. T. AU - Bakris, G. L. AU - McCullough, P. A. PY - 2011 DA - 2011// TI - Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP) JO - Am J Kidney Dis VL - 57 UR - https://doi.org/10.1053/j.ajkd.2010.11.007 DO - 10.1053/j.ajkd.2010.11.007 ID - Stevens2011 ER - TY - JOUR AU - McCullough, P. A. AU - Patanker, G. AU - Stoler, R. C. PY - 2015 DA - 2015// TI - Estimating renal filtration, drug dosing, and clinical outcomes JO - J Am Coll Cardiol VL - 65 UR - https://doi.org/10.1016/j.jacc.2015.05.015 DO - 10.1016/j.jacc.2015.05.015 ID - McCullough2015 ER - TY - JOUR AU - Levey, A. S. AU - Stevens, L. A. AU - Schmid, C. H. PY - 2009 DA - 2009// TI - A new equation to estimate glomerular filtration rate JO - Ann Intern Med VL - 150 UR - https://doi.org/10.7326/0003-4819-150-9-200905050-00006 DO - 10.7326/0003-4819-150-9-200905050-00006 ID - Levey2009 ER - TY - JOUR AU - Becker, B. N. AU - Vassalotti, J. A. PY - 2010 DA - 2010// TI - A software upgrade: CKD testing in 2010 JO - Am J Kidney Dis VL - 55 UR - https://doi.org/10.1053/j.ajkd.2009.11.005 DO - 10.1053/j.ajkd.2009.11.005 ID - Becker2010 ER - TY - JOUR AU - Palsson, R. AU - Waikar, S. S. PY - 2018 DA - 2018// TI - Renal functional reserve revisited JO - Adv Chronic Kidney Dis. VL - 25 UR - https://doi.org/10.1053/j.ackd.2018.03.001 DO - 10.1053/j.ackd.2018.03.001 ID - Palsson2018 ER - TY - JOUR AU - Ronco, C. AU - Chawla, L. S. PY - 2016 DA - 2016// TI - Glomerular and tubular kidney stress test: new tools for a deeper evaluation of kidney function JO - Nephron. VL - 134 UR - https://doi.org/10.1159/000449235 DO - 10.1159/000449235 ID - Ronco2016 ER - TY - JOUR AU - Barai, S. AU - Gambhir, S. AU - Prasad, N. AU - Sharma, R. K. AU - Ora, M. PY - 2010 DA - 2010// TI - Functional renal reserve capacity in different stages of chronic kidney disease JO - Nephrology (Carlton). VL - 15 UR - https://doi.org/10.1111/j.1440-1797.2010.01291.x DO - 10.1111/j.1440-1797.2010.01291.x ID - Barai2010 ER - TY - JOUR AU - Bersoff-Matcha, S. J. AU - Chamberlain, C. AU - Cao, C. AU - Kortepeter, C. AU - Chong, W. H. PY - 2019 DA - 2019// TI - Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases JO - Ann Intern Med UR - https://doi.org/10.7326/m19-0085 DO - 10.7326/m19-0085 ID - Bersoff-Matcha2019 ER - TY - JOUR AU - Scheen, A. J. PY - 2019 DA - 2019// TI - An update on the safety of SGLT2 inhibitors JO - Exp Opin Drug Saf. VL - 18 UR - https://doi.org/10.1080/14740338.2019.1602116 DO - 10.1080/14740338.2019.1602116 ID - Scheen2019 ER - TY - JOUR AU - Aroor PY - 2018 DA - 2018// TI - Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0750-8 DO - 10.1186/s12933-018-0750-8 ID - Aroor2018 ER - TY - JOUR AU - Nasiri-Ansari PY - 2018 DA - 2018// TI - Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0749-1 DO - 10.1186/s12933-018-0749-1 ID - Nasiri-Ansari2018 ER - TY - JOUR AU - Franco, D. i. PY - 2017 DA - 2017// TI - Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target JO - Int J Cardiol VL - 243 UR - https://doi.org/10.1016/j.ijcard.2017.05.032 DO - 10.1016/j.ijcard.2017.05.032 ID - Franco2017 ER - TY - JOUR AU - Soga PY - 2018 DA - 2018// TI - Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0775-z DO - 10.1186/s12933-018-0775-z ID - Soga2018 ER - TY - JOUR AU - Matsutani PY - 2018 DA - 2018// TI - Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0717-9 DO - 10.1186/s12933-018-0717-9 ID - Matsutani2018 ER - TY - JOUR AU - Kim PY - 2018 DA - 2018// TI - Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0737-5 DO - 10.1186/s12933-018-0737-5 ID - Kim2018 ER - TY - JOUR AU - Patorno, E. AU - Goldfine, A. B. AU - Schneeweiss, S. AU - Everett, B. M. AU - Glynn, R. J. AU - Liu, J. AU - Kim, S. C. PY - 2018 DA - 2018// TI - Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study JO - BMJ VL - 6 UR - https://doi.org/10.1136/bmj.k119 DO - 10.1136/bmj.k119 ID - Patorno2018 ER - TY - JOUR AU - Gallwitz, B. PY - 2018 DA - 2018// TI - The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors—real-world data JO - Eur Endocrinol. VL - 14 UR - https://doi.org/10.17925/EE.2018.14.1.17 DO - 10.17925/EE.2018.14.1.17 ID - Gallwitz2018 ER - TY - JOUR AU - Giugliano, D. AU - Meier, J. J. AU - Esposito, K. PY - 2019 DA - 2019// TI - Heart failure and type 2 diabetes: from cardiovascular outcome trials, with hope JO - Diabetes Obes Metab VL - 21 UR - https://doi.org/10.1111/dom.13629 DO - 10.1111/dom.13629 ID - Giugliano2019 ER - TY - JOUR AU - Furberg, C. D. PY - 2000 DA - 2000// TI - Class effects and evidence-based medicine JO - Clin Cardiol VL - 23 ID - Furberg2000 ER - TY - JOUR AU - McCullough, P. A. AU - Kluger, A. Y. AU - Tecson, K. M. AU - Barbin, C. M. AU - Lee, A. Y. AU - Lerma, E. V. AU - Rosol, Z. P. AU - Kluger, S. L. AU - Rangaswami, J. PY - 2018 DA - 2018// TI - Inhibition of the sodium–proton antiporter (Exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2 JO - Rev Cardiovasc Med VL - 19 ID - McCullough2018 ER - TY - JOUR AU - Kaplan, A. AU - Abidi, E. AU - El-Yazbi, A. AU - Eid, A. AU - Booz, G. W. AU - Zouein, F. A. PY - 2018 DA - 2018// TI - Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects JO - Heart Fail Rev VL - 23 UR - https://doi.org/10.1007/s10741-017-9665-9 DO - 10.1007/s10741-017-9665-9 ID - Kaplan2018 ER - TY - JOUR AU - Eckardt, K. U. AU - Bansal, N. AU - Coresh, J. AU - Evans, M. AU - Grams, M. E. AU - Herzog, C. A. AU - James, M. T. AU - Heerspink, H. J. L. AU - Pollock, C. A. AU - Stevens, P. E. AU - Tamura, M. K. AU - Tonelli, M. A. AU - Wheeler, D. C. AU - Winkelmayer, W. C. AU - Cheung, M. AU - Hemmelgarn, B. R. PY - 2018 DA - 2018// TI - Improving the prognosis of patients with severely decreased glomerular filtration rate (CKDG4+): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference JO - Kidney Int VL - 93 UR - https://doi.org/10.1016/j.kint.2018.02.006 DO - 10.1016/j.kint.2018.02.006 ID - Eckardt2018 ER -